The TNX-1800 COVID-19 vaccine by Tonix Pharmaceuticals has been chosen for testing in Project Next Gen, a White House and Department of Health and Human Services initiative. This program is managed by the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID).
Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, made the announcement on Proactive with Steve Darling. The TNX-1800 vaccine utilizes a live virus platform, which stimulates the immune system in a unique way. Compared to mRNA vaccines, this method provides longer-lasting immunity that may potentially prevent transmission.
The selection of TNX-1800 was due to Tonix Pharmaceuticals’ almost ten years of commitment to vaccine development. Additionally, the technology platform can be adapted to protect against other infectious diseases such as monkeypox, smallpox, and tuberculosis.
This decision highlights the importance of vaccine platforms in addressing various infectious threats. Tonix’s approach offers promise for more durable immunity and potential transmission prevention, which could revolutionize our approach to infectious disease control. Moreover, the adaptability of this platform makes it a valuable tool for future vaccine strategies, making it an effective solution for future pandemics.
For more information about TNX-1800 and Tonix Pharmaceuticals, contact Proactive Studio at +1 347-449-0879 or email them at firstname.lastname@example.org.